(Information provided by Commonwealth Pharmaceuticals, British West Indies,
manufacturers of Reticulose)
Patients with Hepatitis A and 18 patients with Hepatitis B were treated with
Reticulose. 9 Patients with Hepatitis A and 17 patients with Hepatitis B
were controls and treated with placebo. The treated patients received
Reticulose for a 15 day period, while the control received saline. Based
upon laboratory findings of several parameters: Prothrombin times, Serum
bilirubin, white blood cell count, and clinical observations, Reticulose
treated patients appeared to show significant improvement. The bilirubin
levels of 83% of patients with Hepatitis B, treated with Reticulose for
15 days were in the normal range in 30 days. None of the control patients
treated with placebo were within normal range in 30 days. Of Hepatitis A
patients treated with Reticulose, 100% showed normal bilirubin after 30
days. Of control patients with Hepatitis A, only 22% were in normal range
after 30 days. The findings in this preliminary trial lead to the
conclusion that Reticulose appears to significantly reduce the recovery
time and return to normal for patients with an acute episode of Hepatitis
A or B. Further study is indicated.
Conclusions: In this preliminary Human Clinical Trial in 53 patients with
Hepatitis A or Hepatitis B, one half of whom were treated with
Reticulose, the results demonstrated positive clinical and laboratory
effects. 18 patients with Hepatitis B and 9 with Hepatitis A were treated
with Reticulose, compared to 17 control patients with Hepatitis B and 9
control patients with Hepatitis A treated with placebo. Patients were
diagnosed for Hepatitis A or B by appropriate laboratory tests of blood,
urine, x-ray and physical examination, with special attention to Anti-HAV
IGM and Hepatitis B surface Antigen to carefully differentiate those with
A from those with B. We realize, however, that liver biopsy is the
positive method for hepatitis diagnosis, but physical limitations
prevented our using this method in this study. Based upon laboratory
findings, serum bilirubin levels of 83% patients with Hepatitis B,
treated with Reticulose for 15 days were in normal range in 30 days, 50%
in 15 days, and 22% in 10 days. None of the control patients were in
normal range after 30 days with placebo treatment. In the Hepatitis A
patients treated with Reticulose, 100% showed normal bilirubin levels
after 30 days, 89% after 15 days, and 33% after 10 days.
In the control patients with Hepatitis A only 22% were in normal range after 30
days, 11% after 15 days, and 11% after 10 days.
In all of the Reticulose treated patients, the white blood cell count showed significant increase, indicating stimulus to the immune system. In all of the Reticulose treated patients, the prothrombin times returned promptly to normal range while the controls did not. The results appear to demonstrate significant improvement in the patients treated with Reticulose, especially those with Hepatitis B. - “The use of Reticulose in the Treatment of Hepatitis A, B & C,” Excerpted from: Journal of the Royal Society of Health Volume 112, No. 6, pages 266-270 December, 1992
